Useful Life vs Economic Life
Useful life is the entity-specific accounting horizon; economic life is broader market viability. Useful life cannot exceed economic life under IAS 38.
Introduction
In intangible asset valuation, the two terms useful life and economic life sometimes get used interchangeably — they describe different but related concepts and the distinction matters in audit. Useful life is the entity-specific period over which the asset is expected to generate benefit for the reporting entity. Economic life is the broader market-wide horizon over which the asset remains commercially viable across all possible users. In the typical case they coincide; in a meaningful minority of cases they diverge, and the divergence affects valuation, amortisation, and impairment testing.
This page compares useful life and economic life as concepts under IAS 38 (UK and global), ASC 350 (US), and FRS 102 Section 18 (UK). It sets out where the two coincide, where they diverge, and how each enters the practitioner's workflow. The reader is assumed to be a valuer, PPA practitioner, or financial controller working on intangible recognition and measurement.
TL;DR: Useful life is the entity-specific accounting horizon — how long this business will derive economic benefit from the asset. Economic life is the broader market-wide commercial viability of the asset across all potential users. Useful life cannot exceed economic life. The two typically coincide when the entity intends to use the asset across its full commercial viability; they diverge when the entity's planned use, technological substitution, or strategic shift shortens the useful life below the economic life. The amortisation period follows the useful life, not the economic life.
Useful Life
Useful life is the period over which a finite-life intangible asset is expected to be available for use by the reporting entity, or the number of production units or similar that the entity expects to obtain from the asset. The definition is entity-specific — it depends on how this particular business intends to deploy the asset, not how the broader market might use it. The anchor is IAS 38.8 (UK and global) and substantively mirrored in ASC 350-30 (US).
How useful life is determined
- Identify the asset's economic life — the period of broader commercial viability
- Identify any legal, regulatory, or contractual ceiling on the asset's life
- Identify any entity-specific factors that might shorten useful life below economic life — planned replacement, technological obsolescence within the entity's roadmap, strategic shift away from the asset
- The useful life is the shortest of the three ceilings: economic, legal, entity-specific
When useful life is shorter than economic life
This is the practical reality of most useful-life assessments. The entity often has shorter horizons than the broader market would imply. Common causes:
- Planned replacement — the entity intends to replace the asset with a successor technology before the asset's commercial viability ends
- Strategic shift — the entity is exiting the market or product line associated with the asset
- Contractual termination — the entity's right to use the asset is limited by a licence or contract that ends before broader economic life
- Technological roadmap — the entity's own technology pipeline will supersede the asset internally even though it remains viable externally
What you need to determine useful life
- Documentation of the asset's economic life (industry benchmarks, comparable assets, technological lifecycle data)
- Documentation of any legal or contractual ceiling (patent expiry, licence term)
- Entity-specific roadmap evidence where useful life is being set below economic life
- Annual review under IAS 38.104 (UK and global) — re-confirm or revise
A pharmaceutical company acquires a patent with 12 years remaining of legal protection. Industry data suggests comparable patents typically retain commercial viability for the full patent term plus a 2-3 year post-expiry tail before full generic erosion — implying economic life of 14-15 years. The acquiring company's strategic roadmap, however, plans to launch a successor compound in year 8 that will internally cannibalise the acquired patent's revenue. Useful life is set at 8 years (entity-specific) — shorter than economic life (14-15 years) and shorter than legal life (12 years).
Useful life is what this entity will derive from the asset. It is bounded above by economic life and by legal life, but it can be shorter than either where entity-specific factors apply. Audit teams accept shorter useful lives when the entity-specific evidence is documented.
Economic Life
Economic life is the period over which an asset remains commercially viable across the broader market — the horizon over which any market participant could derive economic benefit from the asset before commercial obsolescence, substitution, or other erosion makes it commercially unviable. The concept is implicit in IAS 38 (UK and global) — the standard refers to "economic life" in the indicators of useful life at IAS 38.90 — but it is not separately measured for accounting purposes. It is the underlying market reality that constrains the entity-specific useful-life assessment.
How economic life is determined
- Industry-wide observations of comparable assets and their typical commercial viability
- Technology-lifecycle research showing when a class of asset is typically superseded
- Patent or regulatory protection horizons where they cap commercial viability
- Sector-specific behavioural patterns (consumer adoption curves, B2B replacement cycles)
When economic life is the relevant concept
Economic life is the operative concept in several specific contexts:
- Asset-level fair-value determination — IFRS 13 (UK and global) and ASC 820 (US) fair value reflects market-participant assumptions, so the cash-flow projection uses an economic-life horizon (the asset's expected commercial viability to any market participant), not the entity-specific useful life
- Royalty-rate selection in RFR — comparable licensing transactions are observed at the asset's economic-life horizon, not at the entity-specific useful-life horizon
- Impairment testing recoverable amount — fair-value-less-costs-to-sell, where it is the relevant recoverable-amount measure, uses an economic-life horizon
- Strategic planning — economic life informs decisions about portfolio strategy, technology investment, and competitive positioning
What you need to determine economic life
- External market data on comparable assets in the same class
- Technology-lifecycle studies for the relevant asset class (software, pharma, brand, etc.)
- Patent or regulatory protection horizons where applicable
- Industry-wide benchmark studies (PPA precedent databases, valuation practice benchmarks)
- Sector-specific commercial-viability studies
Defensibility profile
Economic life is highly defensible when the practitioner can point to external comparable evidence supporting the horizon — industry studies, benchmark databases, observed transactions. The most common challenge is where economic life is asserted without external support, particularly in fair-value-less-costs-to-sell calculations where the projection horizon is material to the recoverable-amount conclusion.
Economic life is a market-participant concept. Useful life is an entity-specific concept. In a fair-value calculation under IFRS 13 (UK and global) or ASC 820 (US), the cash-flow horizon is economic life (what a market participant would derive); in the subsequent amortisation calculation under IAS 38 (UK and global), the period is useful life (what this entity will derive). The two are aligned in PPA fair-value work, then diverge when the entity-specific useful life is shorter than economic life.
Side-by-Side Comparison
The table below sets out the practitioner's quick-reference view. Each row is a dimension of distinction.
| Criterion | Useful Life | Economic Life |
|---|---|---|
| Perspective | Entity-specific — what this entity will derive | Market-wide — what any market participant could derive |
| Primary anchor | IAS 38.8 (UK and global); ASC 350-30-35 (US) | Implicit in IAS 38.90 (UK and global); economics literature |
| Used in | Amortisation period determination; impairment trigger assessment | Fair-value determination (IFRS 13 / ASC 820); RFR royalty horizon |
| Determined by | Entity-specific roadmap, plus economic and legal ceilings | Industry-wide market data, technology lifecycle, patent / regulatory horizons |
| Reported on | Disclosed under IAS 38.118 (UK and global) and ASC 350 (US) | Not separately disclosed; embedded in fair-value support |
| Annual review | Required under IAS 38.104 (UK and global) | Updated as part of fair-value or impairment work when undertaken |
| Can be indefinite? | Yes under IAS 38 (UK and global); not under FRS 102 Section 18 (UK) | Yes — assets like brands often have indefinite economic life |
| Typically the shorter of the two? | Yes — useful life ≤ economic life | No — economic life is the ceiling |
| Documentation focus | Entity-specific roadmap; planned replacement; strategic shift | External market evidence; benchmark studies; comparable assets |
| Audit attention | Whether useful life is justified relative to economic life | Whether the cash-flow horizon in fair value is market-participant defensible |
| Effect on amortisation | Direct — drives amortisation period and charge | Indirect — drives the underlying valuation that is amortised |
| Effect on RFR royalty rate | Indirect — the rate reflects market practice not entity practice | Direct — the rate is observed at economic-life horizons |
| FRS 102 Section 18 (UK) treatment | Must be finite; 10-year fallback where not reliably estimable | Not separately measured; underlies the useful-life assessment |
| Common pitfall | Stretching useful life to economic life without entity-specific justification | Assuming economic life from anecdote without external benchmarks |
| Where the two diverge | Entity-specific factors shorten useful life below economic life | Always at or above useful life by definition |
How useful life and economic life work together in PPA
In a typical PPA, the two concepts enter the workflow at different steps:
- Step 1 — Fair value determination: Use economic-life horizon for the cash-flow projection (market-participant view under IFRS 13 (UK and global) / ASC 820 (US))
- Step 2 — Useful life determination: Set the entity-specific useful life — the shorter of economic life and any entity-specific roadmap factors
- Step 3 — Amortisation: Apply amortisation over useful life, not economic life
- Step 4 — Subsequent impairment testing: Use economic-life horizon for fair-value-less-costs-to-sell calculations; use useful-life horizon for value-in-use calculations
- Step 5 — Annual review: Reassess useful life under IAS 38.104 (UK and global); reassess underlying economic life inputs where impairment indicators are present
A practitioner who keeps the two distinct produces internally consistent PPA and impairment work. A practitioner who conflates them produces fair-value numbers that do not survive audit.
Use economic life in fair-value work (market-participant cash-flow horizon). Use useful life in amortisation work (entity-specific consumption pattern). The two concepts are bounded by the inequality: useful life ≤ economic life. Where the entity sets useful life below economic life, the documentation must explain the entity-specific reasoning.
FAQ
Are useful life and economic life the same thing?
No, though they often coincide. Useful life is the entity-specific period over which the asset will generate benefit for the reporting entity. Economic life is the broader market-wide commercial viability of the asset across all potential users. Useful life cannot exceed economic life. They coincide when the entity intends to use the asset across its full commercial viability; they diverge when entity-specific factors (planned replacement, strategic shift, contractual termination) shorten useful life below economic life.
When should useful life be shorter than economic life?
When entity-specific factors limit the entity's planned use of the asset relative to broader commercial viability. Common cases: (a) the entity has a successor product in development that will internally replace the asset before economic life ends, (b) the entity is exiting the market or product line associated with the asset, (c) a contractual termination right ends the entity's use before economic life expires, or (d) the entity's own technology roadmap will supersede the asset internally. The defensibility test is whether the entity-specific reasoning is documented at recognition and reviewed annually under IAS 38.104 (UK and global).
Which concept governs fair-value calculations?
Economic life. Fair value under IFRS 13 (UK and global) and ASC 820 (US) is a market-participant measure — it reflects what a market participant would pay for the asset, derived from cash flows that any market participant could generate. The cash-flow horizon is therefore the asset's economic life, not the entity-specific useful life. A practitioner who uses entity-specific useful life in the fair-value cash-flow projection has produced an entity-specific value, not a fair value — and this gets flagged in audit.
Which concept governs amortisation?
Useful life. Amortisation is the systematic allocation of the asset's carrying value to profit and loss over the period the entity expects to benefit from the asset. The period is set by IAS 38.97 (UK and global) and ASC 350-30-35 (US) and reflects the entity-specific consumption of the asset's economic benefits. Using economic life as the amortisation period when the entity has set a shorter useful life is an error that gets flagged.
How does the RFR royalty rate interact with the two concepts?
The royalty rate in RFR is derived from comparable licensing transactions observed across market participants — implicitly an economic-life concept. The royalty rate reflects what an arm's-length licensee would pay for the asset over its commercial viability, not what this entity would extract over its planned use. The RFR cash-flow projection therefore uses economic life as the horizon (matching the market-participant rate), and the resulting fair value is then amortised over the entity-specific useful life (which may be shorter).
What happens when useful life is set materially below economic life?
The entity needs to document the entity-specific reasoning. Material reductions of useful life below economic life often signal an impairment trigger — if the entity now expects to derive benefit from the asset only over 5 years rather than 12, the carrying value supported by the longer cash-flow projection may not be recoverable. Audit teams test whether (a) the useful life reduction is genuinely justified by entity-specific factors and (b) the carrying value remains supportable at the revised horizon.
Does FRS 102 distinguish between the two concepts?
FRS 102 Section 18 (UK) does not separately measure economic life — it operates on useful life only, with the additional constraint that all intangibles must have a finite useful life (no indefinite-life option) and a 10-year fallback where useful life cannot be reliably estimated. The underlying economic-life concept is implicit (it informs the useful-life assessment) but is not separately disclosed. Under IAS 38 (UK and global IFRS), the distinction is more explicit and indefinite-life is permitted for qualifying assets where there is no foreseeable economic-life ceiling.
How does this affect impairment testing?
The recoverable amount under IAS 36 (UK and global) and ASC 350 (US) is the higher of fair-value-less-costs-to-sell and value-in-use. Fair-value-less-costs-to-sell uses an economic-life horizon (market-participant view); value-in-use uses a useful-life horizon (entity-specific consumption). Where the two horizons differ materially, the two recoverable-amount measures will differ — and the higher of them is the recoverable amount. Audit attention concentrates on whether each calculation is internally consistent in its horizon choice.
When to Seek Expert Support
Useful life vs economic life assessments are routine when the entity intends to use the asset across its full commercial viability. They become technically demanding where (a) the entity is setting useful life materially below economic life, (b) the audit team is challenging fair-value cash-flow horizons against economic-life evidence, (c) impairment testing produces materially different recoverable-amount measures under fair-value-less-costs-to-sell versus value-in-use, or (d) FRS 102 transition raises the indefinite-life vs finite-life question.
Opagio's Asset Valuator module (within Opagio Intangibles) captures both useful life (entity-specific) and economic life (market-wide) assumptions in the Value Drivers Register, drives fair-value calculations off economic-life horizons, drives amortisation off useful-life horizons, and produces the audit-trail evidence that supports each judgement.
For complex multi-asset PPAs or where useful life is materially below economic life, the right pattern is to automate the mechanical work and have a qualified specialist review the entity-specific reasoning and the underlying economic-life evidence.
Book a demo: See how Asset Valuator distinguishes useful life and economic life across a multi-asset intangible portfolio with full audit-trail evidence. Book a demo or speak to our team.
Related Glossary Terms
Learn More
Ready to Value Your Intangible Assets?
Use Opagio's valuation tools to apply these methods to your own business.